PMID- 30429712
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220330
IS  - 1642-395X (Print)
IS  - 2299-0046 (Electronic)
IS  - 1642-395X (Linking)
VI  - 35
IP  - 5
DP  - 2018 Oct
TI  - The effect of omalizumab treatment on IgE and other immunoglobulin levels in 
      patients with chronic spontaneous urticaria and its association with treatment 
      response.
PG  - 516-519
LID - 10.5114/ada.2017.71422 [doi]
AB  - INTRODUCTION: Suppression of free immunoglobulin E (IgE) levels and an increase 
      in total IgE levels are observed during omalizumab treatment. However, whether 
      omalizumab has any effect on other immunoglobulins is unknown. AIM: To 
      investigate the effect of omalizumab treatment on serum IgE and other 
      immunoglobulins, and demonstrate any association with response to treatment in 
      patients with chronic spontaneous urticaria (CSU). MATERIAL AND METHODS: The 
      study included 41 patients diagnosed with CSU. Baseline and 
      post-12-week-treatment total IgE, IgA, IgM, and IgG levels and blood eosinophil, 
      neutrophil, lymphocyte and platelet levels were compared. Patients were grouped 
      based on weekly urticaria activity score (UAS-7) responses and these parameters 
      were compared. RESULTS: There was a significant increase in baseline and 
      post-12-week-treatment total IgE levels, while there was no significant 
      difference in other immunoglobulin levels. A significant reduction was found in 
      neutrophil counts after the treatment, whereas there was no significant 
      difference in eosinophil, lymphocyte and platelet levels. There was no difference 
      in these parameters between groups with complete response and without complete 
      response. CONCLUSIONS: Omalizumab treatment can also be used in patients with 
      immunoglobulin deficiency. Due to the observed reduction in neutrophil counts 
      after the treatment, patients must be closely followed for whole blood 
      parameters.
FAU - Cildag, Songul
AU  - Cildag S
AD  - Department of Allergy and Clinical Immunology, Adnan Menderes University, Aydin, 
      Turkey.
FAU - Senturk, Taskin
AU  - Senturk T
AD  - Department of Allergy and Clinical Immunology, Adnan Menderes University, Aydin, 
      Turkey.
LA  - eng
PT  - Journal Article
DEP - 20180719
PL  - Poland
TA  - Postepy Dermatol Alergol
JT  - Postepy dermatologii i alergologii
JID - 101168357
PMC - PMC6232555
OTO - NOTNLM
OT  - chronic urticaria
OT  - immunoglobulin
OT  - omalizumab
EDAT- 2018/11/16 06:00
MHDA- 2018/11/16 06:01
PMCR- 2018/10/01
CRDT- 2018/11/16 06:00
PHST- 2017/06/13 00:00 [received]
PHST- 2017/09/11 00:00 [accepted]
PHST- 2018/11/16 06:00 [entrez]
PHST- 2018/11/16 06:00 [pubmed]
PHST- 2018/11/16 06:01 [medline]
PHST- 2018/10/01 00:00 [pmc-release]
AID - 71422 [pii]
AID - 10.5114/ada.2017.71422 [doi]
PST - ppublish
SO  - Postepy Dermatol Alergol. 2018 Oct;35(5):516-519. doi: 10.5114/ada.2017.71422. 
      Epub 2018 Jul 19.